|
1
|
Andrade FDO, Furtado KS, Heidor R, Sandri S, Hebeda CB, Miranda MLP, Fernandes LHG, Yamamoto RC, Horst MA, Farsky SHP, Moreno FS. Antiangiogenic effects of the chemopreventive agent tributyrin, a butyric acid prodrug, during the promotion phase of hepatocarcinogenesis. Carcinogenesis 2020; 40:979-988. [PMID: 30590392 DOI: 10.1093/carcin/bgy190] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2018] [Revised: 12/04/2018] [Accepted: 12/21/2018] [Indexed: 12/19/2022] Open
Abstract
Agents that inhibit angiogenic factors may prevent the development of hepatocellular carcinoma (HCC). Thus, the objective of this study was to kinetically evaluate the antiangiogenic activity of tributyrin (TB), a butyric acid prodrug, in the promotion stage of hepatocarcinogenesis. For this purpose, the resistant hepatocyte (RH) model was used for induction of preneoplastic lesions in Wistar rats. During the promotion phase, the animals received TB or maltodextrin (MD) as control daily. The rats were killed at three time-points (P1, P2 and P3). Increased expression of Vegfa and Vegfr2 was observed during promotion phase of hepatocarcinogenesis, which was not reversed by TB treatment. However, TB treatment reduced the expression of cluster of differentiation (CD) 34-positive vessels at P3 and α-smooth muscle actin (α-SMA)-positive vessels at P2 compared with MD. Enhanced levels of hypoxia inducible factor-1α (HIF-1α) and phosphorylated extracellular signal-regulated kinases (pERK) were detected at P3 when compared with P1 and P2 in the MD treatment. TB treatment reduced the levels of HIF-1α and pERK at P3 relative to the MD control. Experiments with human umbilical vein endothelial cells (HUVEC) showed that sodium butyrate (NaBu) inhibited cell migration and tube formation, confirming the antiangiogenic activity of its prodrug TB. In conclusion, antiangiogenic activity of TB is an early event that already occurs in preneoplastic livers, reinforcing its potential chemopreventive effects against HCC.
Collapse
Affiliation(s)
- Fabia de Oliveira Andrade
- Laboratory of Diet, Nutrition and Cancer, Department of Food and Experimental Nutrition, University of São Paulo, São Paulo, Brazil
| | - Kelly Silva Furtado
- Laboratory of Diet, Nutrition and Cancer, Department of Food and Experimental Nutrition, University of São Paulo, São Paulo, Brazil
| | - Renato Heidor
- Laboratory of Diet, Nutrition and Cancer, Department of Food and Experimental Nutrition, University of São Paulo, São Paulo, Brazil
| | - Silvana Sandri
- Department of Clinical and Toxicological Analyses, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil
| | - Cristina Bichels Hebeda
- Department of Clinical and Toxicological Analyses, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil
| | - Mayara Lilian Paulino Miranda
- Laboratory of Diet, Nutrition and Cancer, Department of Food and Experimental Nutrition, University of São Paulo, São Paulo, Brazil
| | - Laura Helena Gasparini Fernandes
- Laboratory of Diet, Nutrition and Cancer, Department of Food and Experimental Nutrition, University of São Paulo, São Paulo, Brazil
| | - Roberto Carvalho Yamamoto
- Laboratory of Diet, Nutrition and Cancer, Department of Food and Experimental Nutrition, University of São Paulo, São Paulo, Brazil
| | - Maria Aderuza Horst
- Laboratory of Diet, Nutrition and Cancer, Department of Food and Experimental Nutrition, University of São Paulo, São Paulo, Brazil
| | - Sandra Helena Poliselli Farsky
- Department of Clinical and Toxicological Analyses, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil
| | - Fernando Salvador Moreno
- Laboratory of Diet, Nutrition and Cancer, Department of Food and Experimental Nutrition, University of São Paulo, São Paulo, Brazil
| |
Collapse
|
|
2
|
Ilexgenin A exerts anti-inflammation and anti-angiogenesis effects through inhibition of STAT3 and PI3K pathways and exhibits synergistic effects with Sorafenib on hepatoma growth. Toxicol Appl Pharmacol 2017; 315:90-101. [DOI: 10.1016/j.taap.2016.12.008] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2016] [Revised: 12/09/2016] [Accepted: 12/11/2016] [Indexed: 12/20/2022]
|